Your browser is no longer supported. Please, upgrade your browser.
Settings
MACK Merrimack Pharmaceuticals, Inc. daily Stock Chart
MACK [NASD]
Merrimack Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.32 Insider Own0.70% Shs Outstand118.06M Perf Week-6.47%
Market Cap835.86M Forward P/E- EPS next Y-0.55 Insider Trans11.16% Shs Float105.43M Perf Month-15.41%
Income-148.00M PEG- EPS next Q-0.36 Inst Own71.20% Short Float25.67% Perf Quarter14.75%
Sales89.30M P/S9.36 EPS this Y-66.60% Inst Trans0.03% Short Ratio13.66 Perf Half Y-29.34%
Book/sh-1.59 P/B- EPS next Y41.50% ROA-103.90% Target Price13.75 Perf Year-36.22%
Cash/sh1.57 P/C4.50 EPS next 5Y5.60% ROE99.00% 52W Range5.02 - 13.26 Perf YTD-10.38%
Dividend- P/FCF- EPS past 5Y-15.50% ROI- 52W High-46.61% Beta1.90
Dividend %- Quick Ratio1.90 Sales past 5Y34.50% Gross Margin99.90% 52W Low41.04% ATR0.42
Employees426 Current Ratio1.90 Sales Q/Q-36.90% Oper. Margin- RSI (14)38.47 Volatility4.44% 4.95%
OptionableYes Debt/Eq- EPS Q/Q-352.30% Profit Margin- Rel Volume0.60 Prev Close7.29
ShortableYes LT Debt/Eq- EarningsMay 02 AMC Payout- Avg Volume1.98M Price7.08
Recom1.60 SMA20-11.44% SMA50-4.70% SMA200-16.36% Volume1,186,477 Change-2.88%
Dec-23-15Reiterated Mizuho Buy $16 → $13
Oct-27-15Reiterated Oppenheimer Outperform $13 → $15
Apr-21-15Reiterated Mizuho Buy $13 → $16
Oct-10-14Resumed Oppenheimer Outperform $9 → $11
Jul-08-14Resumed Brean Capital Buy $16
Jun-20-14Reiterated Oppenheimer Outperform $10 → $8.50
Aug-09-13Reiterated Oppenheimer Outperform $12 → $10
Jun-25-13Initiated Mizuho Buy $12
May-08-12Initiated Oppenheimer Outperform $12
Apr-29-16 09:04AM  Drug Stocks Q1 Earnings Preview: AEGR, AERI, MACK, PRTA Zacks
Apr-28-16 01:30PM  ETFs with exposure to Merrimack Pharmaceuticals, Inc. : April 28, 2016 at Capital Cube
Apr-27-16 07:06PM  Merrimack (MACK) Q1 Earnings: What's Ahead for the Stock? Zacks
08:36AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MACK-US : April 27, 2016 at Capital Cube
Apr-21-16 08:00AM  Merrimack Unveils its Latest Antibody Directed Nanotherapeutic, MM-310, at the 2016 AACR Annual Meeting PR Newswire
Apr-20-16 04:30PM  Merrimack Announces Timing of First Quarter 2016 Investor Conference Call PR Newswire
Apr-14-16 04:05PM  Leica Biosystems and Merrimack Pharmaceuticals to Collaborate on Development of a Heregulin Companion Diagnostic for Seribantumab PR Newswire -5.13%
01:21PM  What Is Going On With These Falling Stocks? at Insider Monkey
08:02AM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Eq
Apr-11-16 09:30AM  Zacks Investment Ideas feature highlights: Juno Therapeutics, Genocea Biosciences, Merrimack Pharmaceuticals and BioShares Biotechnology Clinical Trials ETF
08:40AM  3 Biotech Stocks With Scary-High Debt-to-Capital Ratios at Motley Fool
Apr-07-16 04:21PM  Merrimack Pharmaceuticals Inc Rose 28% in March. Here's Why. at Motley Fool
Mar-24-16 07:00AM  Merrimack Announces Inclusion of ONIVYDE® (irinotecan liposome injection) as a Category 1 Treatment Option in the 2016 NCCN Guidelines for Pancreatic Adenocarcinoma PR Newswire
Mar-16-16 04:45PM  Merrimack to Present on Multiple Oncology Programs at the 2016 American Association for Cancer Research Annual Meeting PR Newswire
Mar-14-16 12:39PM  XLV Rose Last Week, but Did It Reach Its 100-Day Moving Average?
Mar-04-16 01:04PM  MERRIMACK PHARMACEUTICALS INC Financials
Mar-03-16 09:38AM  Merrimack Pharmaceuticals, Inc. Value Analysis (NASDAQ:MACK) : March 3, 2016
Mar-02-16 11:49AM  Bears Had the Upper Hand on February 29: IBB Lost 2.8%
10:12AM  Merrimack Pharmaceuticals, Inc. Earnings Analysis: 2015 By the Numbers
08:27AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MACK-US : March 2, 2016
08:15AM  Merrimack Pharmaceuticals (MACK) Jumps: Stock Rises 12.6%
Feb-26-16 03:31PM  Merrimack Q4 Loss in Line with Estimates, Revenues Miss
01:52PM  Edited Transcript of MACK earnings conference call or presentation 25-Feb-16 9:30pm GMT
01:14PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 10-K, Annual Report
Feb-25-16 05:55PM  Merrimack reports 4Q loss
04:21PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:01PM  Merrimack Reports Fourth Quarter 2015 Financial Results PR Newswire
07:07AM  Q4 2015 Merrimack Pharmaceuticals Inc Earnings Release - After Market Close
Feb-22-16 03:02PM  [$$] Buy-Rated Biotechs to Report Earnings at Barrons.com
11:50AM  What's in Store for Merrimack (MACK) this Earnings Season?
Feb-17-16 08:00AM  Merrimack Announces Timing of Fourth Quarter 2015 Investor Conference Call PR Newswire
Feb-12-16 04:51PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers
Feb-11-16 08:30AM  How to Beat the Market with Biotech -- Bluebird bio, Halozyme Therapeutics, Merrimack Pharma, and Kite Pharma Accesswire
Feb-04-16 02:14PM  Merrimack CEO: Face of pharma isn't a bad actor
Jan-20-16 04:36PM  Merrimack Reports Positive Onivyde Data in Pancreatic Cancer +10.39%
Jan-19-16 06:58PM  Updated Data Shows ONIVYDE® (irinotecan liposome injection) Combination Regimen Increased One Year Survival by 63% in Patients with Metastatic Pancreatic Cancer PR Newswire
Jan-13-16 06:24AM  3 Biotech Stocks Under $10 to Trade for Big Breakouts at TheStreet -8.14%
Jan-11-16 08:00AM  Merrimack to Present Updated Overall Survival Analysis of Phase 3 NAPOLI-1 Study of ONIVYDE (irinotecan liposome injection) at the American Society of Clinical Oncology (ASCO) 2016 Gastrointestinal Cancers Symposium PR Newswire -11.55%
Jan-05-16 08:00AM  Merrimack to Present at the 34th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-29-15 08:30AM  A Refreshing Outlook - Research Reports on Cobalt International Energy, Merrimack Pharmaceuticals, Spectranetics and Jinpan International Accesswire
Dec-23-15 04:51PM  Merrimack Alters Endpoint in Cancer Drug Trial, Raises Funds
Dec-22-15 04:39PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Materi
04:16PM  Merrimack Amends MM-121 Phase 2 Clinical Study in Heregulin-Positive Non-Small Cell Lung Cancer to Support Potential Registration PR Newswire
04:15PM  Merrimack Announces Private Placement of $175 Million of Senior Secured Notes PR Newswire
Dec-15-15 11:20AM  Massachusetts biotechs behind one-in-six drugs approved by FDA this year at bizjournals.com
Dec-14-15 02:14PM  Merrimack Pharmaceuticals, Inc. Earnings Analysis: Q3, 2015 By the Numbers -5.61%
Dec-13-15 12:34PM  Do Hedge Funds Love Merrimack Pharmaceuticals Inc (MACK)? at Insider Monkey
Dec-12-15 08:40PM  Do Hedge Funds Love Ollies Bargain Outlet Holdings Inc (OLLI)? at Insider Monkey
Dec-04-15 08:00AM  Merrimack Announces Presentations at the 2015 San Antonio Breast Cancer Symposium PR Newswire +5.31%
Nov-30-15 10:59AM  Merrimack Pharmaceuticals, Inc. Value Analysis (NASDAQ:MACK) : November 30, 2015
08:09AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : November 30, 2015
Nov-25-15 02:24PM  Baxaltas ONIVYDE NAPOLI-1 Study Sends It to Top of Large-Caps
08:14AM  Hedge Funds Are Buying A. Schulman Inc (SHLM) at Insider Monkey
Nov-24-15 05:02PM  Merrimack CFO Brings Banking, Clinical Chops to Role at The Wall Street Journal
Nov-23-15 08:00AM  Merrimack and Baxalta Announce Publication of the ONIVYDE (irinotecan liposome injection) NAPOLI-1 Study in The Lancet PR Newswire +6.06%
Nov-21-15 01:15PM  JPMorgan Likes These 5 Biotech Stocks at TheStreet
Nov-19-15 02:30PM  Gilead Leads a Biotech Rally at TheStreet
Nov-16-15 03:35PM  Momenta's Cancer Study Enrolment Put on Temporary Hold -5.92%
Nov-10-15 03:03PM  Why Merrimack Pharmaceuticals Inc Is Selling Off Today at Motley Fool -9.06%
02:15PM  Merrimack (MACK) Reports Narrower-than-Expected Q3 Loss
Nov-09-15 10:03PM  Edited Transcript of MACK earnings conference call or presentation 9-Nov-15 9:30pm GMT
05:25PM  Merrimack reports 3Q loss
04:21PM  MERRIMACK PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
04:02PM  Merrimack Reports Third Quarter 2015 Financial Results PR Newswire
07:07AM  Q3 2015 Merrimack Pharmaceuticals Inc Earnings Release - After Market Close
Nov-06-15 03:25PM  Will Puma Biotechnology (PBYI) Surprise in Q3 Earnings?
02:55PM  Will Merrimack (MACK) Surprise Estimates in Q3 Earnings?
02:40PM  Will Intercept (ICPT) Beat Estimates in Q3 Earnings?
01:40PM  Will Inovio (INO) Disappoint Investors this Earnings Season?
Nov-05-15 04:25PM  What Awaits Ligand Pharmaceuticals (LGND) in Q3 Earnings?
04:20PM  Will Isis Pharmaceuticals (ISIS) Surprise in Q3 Earnings?
06:42AM  CEO: THIS is biggest threat to pharm research...
Nov-04-15 10:00AM  Merrimack Pharmaceuticals (Nasdaq: MACK) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Nov-03-15 04:05PM  Merrimack to Present Research on Multiple Programs at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PR Newswire
03:40PM  Can Endo International's (ENDP) Q3 Earnings Surprise?
Nov-02-15 05:17PM  Will Geron (GERN) Post a Wider-than-Expected Loss in Q3? +6.85%
05:04PM  Will Aerie (AERI) Post a Wider-Than-Expected Loss in Q3?
05:00PM  Will AVEO (AVEO) Pull a Surprise this Earnings Season?
04:45PM  What's in Store for Conatus (CNAT) this Earnings Season?
04:42PM  What to Expect from Radius (RDUS) This Earnings Season
04:40PM  Can Celldex (CLDX) Surprise Estimates in Q3 Earnings?
04:15PM  Will Qorvo (QRVO) Q2 Earnings Beat on Holistic Growth?
Oct-30-15 04:05PM  Merrimack Announces Timing of Third Quarter 2015 Investor Conference Call PR Newswire
01:40PM  Will Prothena (PRTA) Miss Estimates This Earnings Season?
01:35PM  Will Arena's (ARNA) Q3 Loss be Narrower-than-Expected?
08:19AM  Why biotech could be on the verge of a rebound
Oct-27-15 08:45AM  Top Analyst Upgrades and Downgrades: BioDelivery, Merrimack, Silver Wheaton, Valeant, Weatherford and More at 24/7 Wall St.
08:00AM  Merrimack and Baxalta Announce Enrollment of First Patient in Phase 2 Study of ONIVYDE (irinotecan liposome injection) in Previously Untreated Front-line Metastatic Pancreatic Cancer PR Newswire
Oct-23-15 12:15AM  PharmaEngine Announces U.S. FDA Approves Merrimack's ONIVYDE(TM) (irinotecan liposome injection) PR Newswire +11.02%
Oct-22-15 01:26PM  FDA clears Merrimack's pancreatic cancer drug with warning Reuters -12.99%
01:11PM  Merrimack Announces U.S. FDA Approval of ONIVYDE (irinotecan liposome injection) for the Treatment of Patients with Metastatic Pancreatic Cancer PR Newswire
01:05PM  Merrimack Pharma Wins FDA Approval of Metastatic Pancreatic Cancer Drug
11:40AM  Merrimack Pharma's cancer drug wins FDA approval Reuters
09:05AM  PharmaEngine Announces Taiwan FDA Approval of ONIVYDE (TM) (irinotecan liposome injection) for the Treatment of Metastatic Pancreatic Cancer PR Newswire
02:15AM  Trending Now: MACK
Oct-20-15 10:22AM  Merrimack Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : October 20, 2015
Oct-11-15 07:21AM  Here's Why Merrimack Pharmaceuticals Slumped in September at Motley Fool
Oct-06-15 10:38AM  Merrimack Pharma Could Have FDA Approval Coming; These Analysts Are Buying
Oct-03-15 09:15AM  5 Big FDA Decisions Expected in October at 24/7 Wall St.
Sep-29-15 04:02PM  Five Biotech Stocks That Could Be M&A Targets After the Selloff at Barrons.com -11.38%
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer primarily in the United States. The company offers ONIVYDE that is used for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy. Its therapeutic oncology candidates in clinical development include MM-398, which is in Phase II clinical trials for the treatment of patients with previously untreated, metastatic pancreatic adenocarcinoma; Phase I clinical trials for the treatment of patients with glioma, pediatric solid tumors, and gastrointestinal tumors; and Phase I clinical trials for treating metastatic breast cancer. The company's therapeutic oncology candidates also include MM-302 that is in Phase II clinical trials for the treatment of patients with ErbB2 (HER2) positive, locally advanced or metastatic breast cancer; and MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer. In addition, its therapeutic oncology candidates consist of MM-141 that is in Phase II clinical trials for the treatment of previously untreated metastatic pancreatic cancer patients who have high serum levels of free IGF-1; and MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has license and collaboration agreements with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA; development, license, and supply agreement with Watson Laboratories, Inc.; sublicense and collaboration agreement with PharmaEngine, Inc.; collaboration agreements with Dyax Corp. and Adimab LLC,; and license agreement with University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PORTER MICHAEL EDirectorMar 17Buy7.205,00036,000754,448Mar 21 09:25 AM
PORTER MICHAEL EDirectorMar 15Buy7.655,00038,250749,448Mar 17 10:51 AM
PORTER MICHAEL EDirectorMar 08Buy7.0910,00070,900744,448Mar 10 09:28 AM
PORTER MICHAEL EDirectorMar 03Buy6.2710,00062,700734,448Mar 04 09:02 AM
PORTER MICHAEL EDirectorMar 02Buy6.635,00033,150724,448Mar 04 09:02 AM
PORTER MICHAEL EDirectorMar 01Buy6.6010,00066,000719,448Mar 02 11:13 AM
McClements William M.Head of Corporate OperationsFeb 29Buy5.722,00011,44014,072Mar 01 01:54 PM
PORTER MICHAEL EDirectorFeb 29Buy5.6110,00056,100709,448Mar 02 11:13 AM
Lee Vivian SDirectorFeb 29Buy5.5035,000192,50065,000Feb 29 02:57 PM
Stewart Edward J.Head of CommercialJan 05Option Exercise1.814,0007,24025,385Jan 07 06:41 PM
Stewart Edward J.Head of CommercialJan 05Sale8.004,00032,00021,385Jan 07 06:41 PM
Stewart Edward J.Head of CommercialDec 01Option Exercise1.815,0009,05026,385Dec 03 04:53 PM
Stewart Edward J.Head of CommercialDec 01Sale9.335,00046,65021,385Dec 03 04:53 PM
Stewart Edward J.Head of CommercialOct 16Option Exercise1.811,0001,81022,385Oct 16 07:09 PM
Stewart Edward J.Head of CommercialOct 16Sale10.001,00010,00021,385Oct 16 07:09 PM
Stewart Edward J.Head of CommercialOct 02Option Exercise1.811,0001,81022,385Oct 05 04:11 PM
Stewart Edward J.Head of CommercialOct 02Sale9.001,0009,00021,385Oct 05 04:11 PM
Stewart Edward J.Head of CommercialOct 01Option Exercise1.814,0007,24025,385Oct 05 04:11 PM
Stewart Edward J.Head of CommercialOct 01Sale8.004,00032,00021,385Oct 05 04:11 PM
Stewart Edward J.Head of CommercialSep 01Option Exercise1.816,00010,86027,385Sep 01 04:11 PM
Stewart Edward J.Head of CommercialSep 01Sale9.886,00059,28021,385Sep 01 04:11 PM
PORTER MICHAEL EDirectorAug 21Buy9.765,00048,800699,448Aug 25 09:13 AM
Stewart Edward J.Head of CommercialAug 17Option Exercise1.816,00010,86027,385Aug 19 04:09 PM
Stewart Edward J.Head of CommercialAug 17Sale10.496,00062,94021,385Aug 19 04:09 PM
PORTER MICHAEL EDirectorAug 14Buy10.183,00030,540694,448Aug 17 09:00 AM
PORTER MICHAEL EDirectorAug 13Buy10.6510,000106,500691,448Aug 17 09:00 AM
Dineen John M.DirectorAug 12Buy10.15100,0001,015,000100,000Aug 13 08:34 AM
PORTER MICHAEL EDirectorAug 12Buy10.1620,000203,200681,448Aug 13 08:30 AM
Lee Vivian SDirectorAug 12Buy10.0510,000100,50030,000Aug 14 09:21 AM
Stewart Edward J.Head of CommercialJul 15Option Exercise1.816,00010,86027,385Jul 17 04:10 PM
Sullivan William A.CFO and TreasurerJul 15Option Exercise2.1215,00031,80026,000Jul 17 04:11 PM
Stewart Edward J.Head of CommercialJul 15Sale11.846,00071,04021,385Jul 17 04:10 PM
Sullivan William A.CFO and TreasurerJul 15Sale11.8515,000177,75011,000Jul 17 04:11 PM
Nielsen Ulrik B.DirectorJun 19Option Exercise2.5640,000102,400266,811Jun 19 09:04 PM
Nielsen Ulrik B.DirectorJun 19Sale12.0240,000480,800226,811Jun 19 09:04 PM
Stewart Edward J.Head of CommercialJun 18Option Exercise1.812,0003,62023,385Jun 19 09:04 PM
Stewart Edward J.Head of CommercialJun 18Sale12.002,00024,00021,385Jun 19 09:04 PM
Stewart Edward J.Head of CommercialJun 15Option Exercise1.816,00010,86027,385Jun 15 06:12 PM
Sullivan William A.CFO and TreasurerJun 15Option Exercise2.1215,00031,80026,000Jun 15 06:13 PM
Sullivan William A.CFO and TreasurerJun 15Sale10.6515,000159,75011,000Jun 15 06:13 PM
Stewart Edward J.Head of CommercialJun 15Sale10.676,00064,02021,385Jun 15 06:12 PM
Schoeberl Birgit M.Head of DiscoveryJun 09Option Exercise2.1262,057131,56165,657Jun 11 08:23 AM
Nielsen Ulrik B.DirectorMay 19Option Exercise2.4740,00098,800266,811May 19 05:04 PM
Nielsen Ulrik B.DirectorMay 19Sale13.0440,000521,600226,811May 19 05:04 PM
Sullivan William A.CFO and TreasurerMay 15Option Exercise2.1215,00031,80026,000May 19 05:02 PM
Stewart Edward J.Head of CommercialMay 15Option Exercise1.818,00014,48029,385May 19 05:03 PM
Stewart Edward J.Head of CommercialMay 15Sale12.338,00098,64021,385May 19 05:03 PM
Sullivan William A.CFO and TreasurerMay 15Sale12.3715,000185,55011,000May 19 05:02 PM
PORTER MICHAEL EDirectorMay 13Buy11.798,28497,668661,448May 15 07:53 AM